This appeal arose in the context of a February 15, 2017 decision of the Minister of Health and Social Services (the "Minister") to halt coverage of Janssen's REMICADE (with certain exceptions, including patients who had previously been receiving REMICADE), and to require that Quebec only pay for the less expensive biosimilar version of infliximab. On January 16, 2019, the Quebec Court of Appeal found the Minister's decision to delist REMICADE from Quebec's Liste des médicaments (the "List") (the Quebec equivalent to a formulary) to be invalid and ordered the Minister to reinstate the drug on the List: Janssen Inc c Ministre de la Santé et des Services sociaux, 2019 QCCA 39. In allowing the appeal, the Court did not comment on the merits of delisting REMICADE, instead holding that (1) the Minister's decisions to list or delist individual drugs are administrative and not regulatory in nature; and (2) a decision to delist a drug may require the Minister to respect certain minimum standards of procedural fairness. The Court concluded that the Minister had violated procedural fairness and should have given Janssen formal notice and an opportunity to respond before making the change. On February 11, 2019, the Minister published an amendment to the List, reinstating full coverage of REMICADE.
Related Publications & Articles
-
Health Canada publishes guidance on submitting risk management plans
The agile licensing amendments to the Food and Drug Regulations include provisions requiring risk management plans for certain human drugs (RMP provisions). Those amendments will come into force on Ap...Read More -
Health Canada seeks input on new draft guidance for co-packaged drug products
On March 18, 2025, Health Canada released a Notice that it is seeking feedback on a draft guidance on co-packaged drug products.Read More -
Canada’s Drug Agency releases 2025 Watch List highlighting AI technologies in health care
On March 25, 2025, Canada’s Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada...Read More